Inclusion Criteria:  Patients of both genders, over 18 years. Patients that undergo the first, second or subsequent recurrences of CD infection, as long as they have completed at least one course of treatment with standard oral antibiotic (vancomycin) in the primary episode and which has ended at least 48 hours before the enrollment of the subject in the study. Presence of an episode of diarrhea defined as ≥3 stools/24 hours. Confirmation of the presence of CD toxin A and/or B in faeces, by a direct toxin detection test or by the PCR technique for the detection of A and/or B toxin producing genes, within 48 hours prior to the enrolment of the subject in the clinical trial.  Exclusion Criteria:  Previous faecal microbiota transfer. Active inflammatory bowel disease (ulcerative colitis, Crohn's disease, or microscopic colitis). Diagnosis of irritable bowel syndrome (IBS) according to Rome III criteria. Transplanted patients, except those with a solid organ transplant of more than 2 years, with good organ function. Absolute neutrophil count <500 cells /μL at the time of the enrollment in the study. Pregnancy, breastfeeding, or pregnancy intentions over the course of the study. Active treatment with bile acid sequestrants (for instance: cholestyramine). Positive patients for the human immunodeficiency virus (HIV) except those with lymphocytes T CD4 count > 200 cells/μL and viral load less than 20 copies. Active or refractory neoplasia. Radiotherapy in the intestinal area, previous or in progress, or active chemotherapy in the last 90 days. Swallowing dysfunction or no oral motor coordination. Patient admitted in an intensive care unit or expected to be admitted in an intensive care unit due to serious illness and with indication of treatment with antibiotic.